CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pharmesis International Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pharmesis International Ltd.
5 Kallang Sector #03-02,
Phone: +65 68460766p:+65 68460766 CHENGDU, SIC  349279  Singapore Ticker: BFKBFK
Business Summary
Pharmesis International Ltd. is a Singapore-based investment holding company. The principal activities of the Company and its subsidiaries are development, manufacture, packaging and sale of western medicine, traditional Chinese medicine (TCM), health tonic products, wholesale of drugs, raw products, antibiotics and antibiotic agents. Its pharmaceutical products are sold in the People’s Republic of China (PRC). The Company’s segments include Western drugs, TCM formulated drugs, and Distribution. The Western drugs segment refers mainly to chemically formulated drugs marketed under the Kinna brand. The TCM formulated drugs segment refers to traditional Chinese medicine marketed under the Longlife brand. Distribution segment refers to agency products and internally manufactured products which are marketed through the distribution arm. Its subsidiaries include Chengdu Kinna Pharmaceutical Co., Ltd and Sichuan Longlife Pharmaceutical Co., Ltd.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Non-Independent Chairman of the Board Heng ChingChew 72 4/30/2024 11/9/2005
Chief Executive Officer, Executive Director XuedanWu 61 12/31/2017 4/16/2004
Financial Controller Chan HoeLiang 39 6/1/2016 6/1/2016
5 additional Officers and Directors records available in full report.

Business Names
Business Name
BFK
Pharmesis International Ltd.

General Information
Outstanding Shares: 31,700,000 (As of 6/30/2024)
Shareholders: 1,131
Stock Exchange: SIN
Fax Number: +65 67740269


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025